Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.

European journal of clinical pharmacology - 1 Nov 2018

Tanaka Hironari, Naito Takafumi, Sato Hikaru, Hiraide Takanori, Yamada Yasuhide, Kawakami Junichi

Abstract excerpt

PURPOSE: Clinical responses to oral tramadol show a large variation in cancer patients. This study aimed to evaluate the impacts of cytochrome P450 (CYP) genotype and serum inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients. METHODS: The predose plasma concentrations of tramadol and its demethylated metabolites were determined at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Analgesics, Opioid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asian People

Share to C-Reactive Protein

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 Enzyme System

Share to Interleukin-6

Share to Neoplasms

Source

Identifiers

PMID: 30051214
DOI: 10.1007/s00228-018-2527-0

Genes

CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.PMID 30051214Read ↗

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.Semantic proximity Read ↗

Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.Semantic proximity Read ↗

Metabolic ratios and SNPs implicated in tramadol-related deaths.Semantic proximity Read ↗

Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.Semantic proximity Read ↗

Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.Semantic proximity Read ↗

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.Semantic proximity Read ↗

Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.Semantic proximity Read ↗

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.Semantic proximity Read ↗

Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.Semantic proximity Read ↗

The Effect of CYP2D6 Gene Polymorphism on Tramadol Efficacy in Total Knee Arthroplasty.Semantic proximity Read ↗

Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.